Skip to main content

Synthetic Biologics, Inc. (SYN)

NYSEAMERICAN: SYN · IEX Real-Time Price · USD
0.406 -0.020 (-4.69%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap53.61M
Revenue (ttm)n/a
Net Income (ttm)-20.46M
Shares Out132.04M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,776,974
Open0.426
Previous Close0.426
Day's Range0.385 - 0.426
52-Week Range0.283 - 1.700
Beta1.81
AnalystsBuy
Price Target1.88 (+363.1%)
Est. Earnings DateNov 9, 2021

About SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant...

IndustryBiotechnology
IPO DateJun 26, 2006
CEOSteven Shallcross
Employees10
Stock ExchangeNYSEAMERICAN
Ticker SymbolSYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.88, which is an increase of 363.05% from the latest price.

Price Target
$1.88
(363.05% upside)
Analyst Consensus: Buy

News

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal A...

ROCKVILLE, Md., Oct. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 days ago - PRNewsWire

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

2 weeks ago - PRNewsWire

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

1 month ago - PRNewsWire

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:AVIRHSTONRBONVIVPRVB
1 month ago - InvestorPlace

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be H...

ROCKVILLE, Md., Aug. 5, 2021 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 months ago - PRNewsWire

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

ROCKVILLE, Md., August 3, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

2 months ago - PRNewsWire

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021

ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 months ago - PRNewsWire

3 Biotech Penny Stocks That You Need to Know About In 2021

Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:NRBONVIV
3 months ago - PennyStocks

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical...

ROCKVILLE, Md., June 29, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

3 months ago - PRNewsWire

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

4 months ago - PRNewsWire

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and...

5 months ago - PRNewsWire

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

5 months ago - PRNewsWire

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic...

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

6 months ago - PRNewsWire

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline ...

ROCKVILLE, Md., April 1, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

6 months ago - PRNewsWire

Synthetic Biologics: 6 Things for SYN Stock Investors to Know as the Biotech Skyrockets

Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to Know as t...

9 months ago - InvestorPlace

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha